Development of epidermicin NI01 for nasal decolonization

世界卫生组织指出，由抗生素耐药性细菌（例如MRSA）引起的感染是当前对公共卫生的最大威胁之一，迫切需要新型抗生素来对抗耐药性感染。我们发现了表皮霉素，一种令人兴奋的重要的新抗生素，可以迅速杀死MRSA和其他细菌。这种新的抗生素比现有的抗生素活性更高，无毒，细菌不会对它产生耐药性。这些都是现有抗生素的显著优势，因此我们计划开发表皮霉素用于临床。鼻子中携带MRSA的人有很高的感染和传播MRSA的风险，所以我们将研究表皮霉素从鼻子中去除MRSA的有效性。我们还将进行旨在帮助我们了解表皮霉素如何杀死细菌以及为什么它们不会产生耐药性的实验，并开展工作以确保抗生素在临床使用时无毒。

The World Health Organisation have stated that infections caused by antibiotic resistant bacteria (e.g. MRSA) are one of the greatest current threats to public health and there is an urgent need for novel antibiotics to combat drug resistant infections. We have discovered epidermicin, an exciting and important new antibiotic that rapidly kills MRSA and other bacteria. The new antibiotic is more active than current antibiotics, is non-toxic and bacteria don't develop resistance to it. These are significant advantages over current antibiotics so we plan to develop epidermicin for clinical use. People who carry MRSA in the nose have a high risk of developing infection and transmitting MRSA, so we will examine how effective epidermicin is for removing MRSA from the nose. We will also carry out experiments designed to help us to understand how epidermicin kills bacteria and why they do not become resistant and carry out work to ensure that the antibiotic is not toxic when used clinically.